RTP Mobile Logo

Sunday, April 12, 2026, San Juan, Puerto Rico, 1:30 PM – 3:00 PM Atlantic Standard Time (UTC-4)

Expert Second Opinion: Investigators Provide Perspectives on the Best-Practice Management of Ovarian Cancer

An Independent CME Symposium During the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women’s Cancer®

Register for in-person Register for webcast

Event Details

Program Schedule — Atlantic Standard Time (UTC-4)
1:00 PM – 1:30 PM — Registration and Lunch Buffet
1:30 PM – 3:00 PM — Educational Meeting

Location
Puerto Rico Convention Center
100 Convention Boulevard
San Juan, Puerto Rico
Phone: +1 (787) 641-7722

Meeting Room
Ballroom A (Level 3)

No registration fee is charged for this event. For the in-person symposium in San Juan, preregistration is advised as seating is limited.  
 
Faculty
Nicoletta Colombo, MD
Director, Gynecologic Oncology Program
European Institute of Oncology IRCCS
Milan, Italy

Gottfried E Konecny, MD
Professor of Medicine and Ob/Gyn
Director, Medical Gynecologic Oncology
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Alexander B Olawaiye, MD
Professor
Department of Obstetrics, Gynecology and Reproductive Sciences
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Moderator
Shannon N Westin, MD, MPH, FASCO, FACOG
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas



This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Agenda

Program Schedule — Atlantic Standard Time (UTC-4)
1:00 PM – 1:30 PM — Registration and Lunch Buffet
1:30 PM – 3:00 PM — Educational Meeting

MODULE 1: Current Role of PARP Inhibitors in Therapy for Advanced Ovarian Cancer (OC) — Prof Colombo

  • Optimal approaches to biomarker testing for patients with newly diagnosed advanced OC; significance of somatic and germline BRCA mutations and homologous recombination deficiency status in treatment decision-making
  • Long-term findings, including overall survival (OS) outcomes, with olaparib, olaparib/bevacizumab and niraparib maintenance for patients with newly diagnosed OC
  • Clinical, biological and practical factors affecting the selection of up-front olaparib, olaparib/bevacizumab and niraparib maintenance
  • Ongoing Phase III studies, such as the MONO-OLA1 and NRG-GY036 trials, further exploring up-front PARP inhibitor maintenance therapy
  • Current clinical utility, if any, of PARP inhibitors for patients with relapsed/refractory OC, including among those who have experienced disease progression after prior PARP inhibitor therapy

MODULE 2: Strategies Targeting Folate Receptor Alpha (FRα) in Advanced OC — Dr Westin

  • Incidence and clinical relevance of FRα expression in OC; optimal approaches to and timing of FRα testing
  • Long-term data, including OS findings, with mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant OC from the Phase III MIRASOL trial
  • FDA approval of mirvetuximab soravtansine for FRα-positive, platinum-resistant OC; implications for biomarker assessment and current management
  • Key findings from the Phase II PICCOLO trial of mirvetuximab soravtansine for FRα-positive, platinum-sensitive OC; ongoing Phase III evaluation in the GLORIOSA trial
  • Mechanistic similarities and differences between investigational FRα-targeted antibody-drug conjugates, such as rinatabart sesutecan and torvutatug samrotecan, and mirvetuximab soravtansine
  • Early data with and ongoing Phase III evaluation of investigational FRα-targeted antibody-drug conjugates in FRα-expressing, platinum-resistant OC

MODULE 3: Other Novel Agents and Strategies for Advanced OC Treatment — Dr Olawaiye

  • Mechanism of antitumor activity of the selective glucocorticoid receptor modulator relacorilant and rationale for its evaluation in treatment for advanced OC
  • Key efficacy and safety findings, including OS data, from the Phase III ROSELLA study of relacorilant with nab paclitaxel versus nab paclitaxel alone for patients with platinum-resistant advanced OC
  • Tolerability profile of relacorilant/nab paclitaxel in the ROSELLA study; relative contributions of each agent in terms of toxicities
  • Recent FDA approval of relacorilant in combination with nab paclitaxel for patients with platinum-resistant OC who have received 1 to 3 prior systemic treatment regimens, at least 1 of which included bevacizumab; current role in clinical practice
  • Available data, including OS outcomes, from the Phase III KEYNOTE-B96 study evaluating the addition of pembrolizumab to chemotherapy with or without bevacizumab for patients with platinum-resistant recurrent OC
  • Recent FDA approval of pembrolizumab in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant recurrent OC; current clinical role
  • Other promising novel agents and strategies nearing the clinic for patients with advanced OC

MODULE 4: Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Konecny

  • Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors for patients with OC
  • Optimal mitigation, monitoring and management of common PARP inhibitor-related toxicities
  • Reported risk of long-term, serious side effects, such as acute myeloid leukemia/myelodysplastic syndromes, with PARP inhibitor therapy
  • Pathogenesis and incidence of ocular adverse reactions associated with mirvetuximab soravtansine
  • Recommended approaches to monitoring, preventing and ameliorating mirvetuximab soravtansine-associated ocular toxicities
  • Spectrum, frequency, severity and management of other side effects, such as peripheral neuropathy, gastrointestinal toxicities, fatigue and pneumonitis, in patients receiving mirvetuximab soravtansine

CE Information

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and appropriately counsel patients regarding personalized treatment recommendations.
  • Appraise biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
  • Recognize the rationale for targeting FRα in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates.
  • Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the current role of this novel therapeutic strategy.
  • Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and recall available and emerging Phase III findings with this novel approach.
  • Recognize adverse events associated with therapeutic approaches commonly employed for OC, and implement strategies to educate patients and manage complications.
  • Describe the scientific justification for, published research data with and current research studies of novel agents and strategies for OC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — Dr Konecny has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Prof Colombo — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, BioNTech SE, Corcept Therapeutics Inc, Eisai Inc, Gilead Sciences Inc, GSK, ImmunoGen Inc, Lilly, MSD, Novocure Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: Incyte Corporation; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, MSD. Dr Olawaiye — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, GSK, Lilly, Merck; Consulting Agreements: Corcept Therapeutics Inc; Speakers Bureaus: Foundation Medicine.

MODERATOR
Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, pharmaand GmbH, Pfizer Inc, Verastem Inc, Zentalis Pharmaceuticals.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location

Puerto Rico Convention Center
100 Convention Boulevard
San Juan, Puerto Rico 00907
Phone: +1 (787) 641-7722

Meeting Room
Ballroom A (Level 3)

Directions
The Puerto Rico Convention Center is the main venue for the 2026 SGO Annual Meeting on Women’s Cancer.

 

Registration

This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

There is no registration fee for this event. For the in-person symposium in San Juan, preregistration is advised as seating is limited.

NOTICE
Registration for this event is independent of registration for the 2026 SGO Annual Meeting on Women’s Cancer.

IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.